Sudarshan Pharma Industries has terminated its proposal to acquire 9.50% equity shares of common stock in Med Therapy Biotechnology Inc., USA. The company informed the BSE that the acquisition plan, previously disclosed in September, is now officially called off.

The termination also extends to the parallel proposal involving the company's promoters. Mr. Hemal Mehta, Chairman and Managing Director, and Mr. Sachin Mehta, Joint Managing Director, had planned to acquire 1.50% each of the equity shares of common stock of Med Therapy. These individual promoter acquisitions also stand terminated as per the latest disclosure.

Regulatory Disclosure Details

The company filed this update pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This notice serves as a continuation of earlier letters dated September 5, 2026, and September 15, 2026, which provided updates on the acquisition of M/s. Med Therapy Biotechnology Inc., USA.

The filing confirms that the Board of Directors has taken note of the termination. The document was signed by Hemal Mehta on October 7, 2026.

Deal Structure Overview

The original proposal involved both corporate and promoter-level investments in the US-based entity. The table below outlines the specific stakes that have been withdrawn:

This development marks the end of the company's immediate expansion efforts into the US biotechnology sector through Med Therapy Biotechnology Inc.

Sudarshan Pharma Industries Ltd has completed the sale of its entire 51% equity stake in unlisted subsidiary Ishwari Healthcare Private Limited for a total consideration of ₹1.40 crore.

The transaction involved the transfer of 2,09,100 equity shares, each with a face value of ₹10, to Mr. Amit Jatin Mehta. Following this divestment, Sudarshan Pharma's shareholding in Ishwari reduced from 51% to nil, resulting in the entity ceasing to be a subsidiary of the company.

Transaction details

The sale was executed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed the completion of the deal on September 28, 2026, following an initial intimation regarding the stake sale on August 13, 2026.

Strategic shift

This move marks a complete exit from the healthcare subsidiary. The reduction in holding from a controlling majority to zero indicates a strategic decision to streamline operations by removing Ishwari Healthcare from the consolidated group structure. The transaction value implies an effective price of approximately ₹66.95 per share, derived from the total consideration divided by the number of shares sold.

What the numbers show

The sale price of ₹1.40 crore for a 51% stake values the entire equity of Ishwari Healthcare at approximately ₹2.75 crore. This valuation suggests that the subsidiary was likely a small-scale or non-core asset within Sudarshan Pharma's portfolio. The exit simplifies the corporate structure by eliminating minority interest complications and reducing administrative overhead associated with managing a non-listed subsidiary.